Description
Influenza is a major respiratory pathogen and vaccination is the main method of prophylaxis. In 2012, the trivalent live attenuated influenza vaccine (LAIV3) was licensed in Europe for use in children. Vaccine-induced antibodies directed against the main viral surface glycoproteins, haemagglutinin (HA) and neuraminidase (NA), play an important role in limiting virus infection. Antibodies to the HA inhibit virus attachment to the host cell receptors and can be measured by the Haemagglutinin inhibition (HI) assay. Neutralizing antibodies (microneutralizing (MN) antibody, virus neutralizing antibody (VN)) as well as non-neutralizing antibodies (ADCC antibody) are also associated with reduce influenza viral infection. The objective of this study was to dissect the overall antibody responses induced after LAIV3 immunization to the influenza A viruses in children and adults.
Plasma was collected at regular time intervals from 20 children and 20 adults pre- and post-LAIV3 vaccination (up to a year) and analysed using a variety of serological assays. Previously we published that LAIV3 elicited H3-head and low levels of H1 stalk specific antibody responses in children, supporting the prophylactic use of LAIV in children [1]. In our recent data, we further showed no increase in MN antibody response post LAIV vaccination against H1N1. H1N1 stalk specific neutralizing and NI antibodies were boosted in children after LAIV. A trend of an increase in ADCC antibodies was observed after vaccination although not significant. Overall no increase in traditional serological HI and MN antibodies was observed in adults or children, however H1 NI and stalk specific antibodies increased in the children. The results indicate that these methods are more sensitive to qualitative changes in serum antibodies. This warrants that further exploration of using the HIN1 method for evaluating vaccine efficacy after LAIV vaccination.
- Islam, S., et al., Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination. Vaccine, 2017. 35(42): p. 5666-5673.
| Choose primary session | Vaccines and antivirals |
|---|
